Post‐Marketing Safety of Ustekinumab Based on 14‐Year Follow‐Up in Danish National Patient Data
Sejun Kim, Andreas Jensen, Alexander Egeberg, Lone Graff Stensballe · 2024
Read Post‐Marketing Safety of Ustekinumab Based on 14‐Year Follow‐Up in Danish National Patient Data by Sejun Kim, Andreas Jensen, Alexander Egeberg, Lone Graff Stensballe (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11599636.txt.
Description
Four researchers led by Sejun Kim checked the long-term safety of ustekinumab, a biologic drug for psoriasis, using Danish national patient records. The study spanned fourteen years and compared the drug with older whole-body treatments and with three newer biologic classes. Outcomes were cancers, heart events, serious infections, and severe allergic reactions.
Users of the drug were younger on average than the comparison groups. Across all comparisons, no clear safety signal stood out for the drug on any outcome, with or without joint disease. Risk estimates shifted by comparison group but stayed reassuring. The authors present the record as support for the drug's lasting safety in routine care.
Catalog record
| CREATOR | Sejun Kim, Andreas Jensen, Alexander Egeberg, Lone Graff Stensballe |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |